2024年EADV大会:Galderma介绍了纳莫利祖马布在治疗亚托皮炎和结节炎的长期疗效和安全性. 2024 EADV congress: Galderma presents long-term efficacy and safety of nemolizumab for atopic dermatitis and prurigo nodularis.

Galderma将在2024年阿姆斯特丹EADV大会上分享ARCADIA和OlYMPIA临床试验的新结果。 Galderma will share new findings from the ARCADIA and OLYMPIA clinical trials at the 2024 EADV congress in Amsterdam. 这些数据将突出尼莫利祖马布在治疗中度至重度的亚托皮炎和结节炎的长期疗效和安全性. The data will highlight the long-term efficacy and safety of nemolizumab for treating moderate-to-severe atopic dermatitis and prurigo nodularis. 结果显示皮肤病变,和生活质量持续改善,安全性概况一致. Results indicate sustained improvements in skin lesions, itch, and quality of life, with a consistent safety profile. 尼莫利祖马布针对IL-31细胞因子信号传递,解决这些疾病的关键症状. Nemolizumab targets IL-31 cytokine signaling, addressing key symptoms of these conditions.